Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.
FAIL · Does not pass the screen
3.51 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price3.51 USD at the 4 Nov 2026 close
Fair value3.01. Our model only; only one analyst covers it, too few to cross-check it.
Our value readOvervalued vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.51 USD
Fair value3.01Our model only; only one analyst covers it, too few to cross-check it.
Ethical score64.7/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-28Read Accumulation3.45+1.9% to today ✓Markdown gives way to Accumulation after an 8% rise in 7 days
2026-10-21Read Markdown3.20+9.7% to today Accumulation gives way to Markdown
2026-10-02Read Accumulation3.33+5.4% to today ✓Markup gives way to Accumulation after a 22% rise in 13 weeks
2026-07-02Read Markup2.74+28.1% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cronos Group Inc. holds its Accumulation at $3.51. Consolidating, no directional conviction, held for 40 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 40 days
Price at the screen
$3.51
Valuation
18.13 trailing · -86.13 forward price to earnings
Values screen
FAIL· score 64.7
Beta
1.20
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.13%
Below 33%
Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
3.34%
Below 33%
Cash held in interest-bearing accounts and securities is 3.3% of assets, under the one-third limit.
Pass
Receivables
68.99%
Below 49%
Money owed to the company is 69.0% of assets, above the 49% limit.
Fail
Revenue purity
27.26%
Below 5%
27.3% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Cronos's business is fine, but its receivables are about 69% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRON's ethical verdict changes
Today CRON does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $3.01 fair value estimate, 58.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 16.6% above the base estimate.
Reading the gap · Both our model and the Street see limited upside at this price.
Where our models see it going: fair-value estimate $3.01, range not available, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cannabis Sales Rise Yet Losses Keep Mounting
Picture a grower shipping dried flowers, oils and edibles from Canada into new markets. Cronos is lifting revenue 40% a year, yet it still runs at a 1% negative profit margin and zero return on equity while the shares sit 9% above our fair value.
The forward multiple is deeply negative and only one analyst even follows the name. Without a clear moat or path to sustained profits, the business offers no margin of safety and earns an opportunity rating of none despite clearing the ethical screen.
Currency swings, shifting cannabis rules and thin cash generation keep risk elevated. The valuation already prices in better days that have not arrived. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Canada and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRON trades on Nasdaq (the company is based in Canada). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$3.38-1.9%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-10-28Accumulation · changed$3.45+7.7%Entry 9
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-10-21Markdown · changed$3.20-0.9%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-10-14Accumulation$3.23-3.0%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-10-02Accumulation · changed$3.33+5.4%Entry 6
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-08-25Markup$3.16+13.3%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-07-25Markup$2.79+1.8%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-07-18Markup$2.74+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-07-03Markup$2.74+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$2.74Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
